Click here to close now.

SYS-CON MEDIA Authors: Carmen Gonzalez, Liz McMillan, Pat Romanski, Marty Puranik, Marco Meinardi

News Feed Item

Study Comparing Canada and Europe Debunks the Myth That Faster Drug Approvals Will Increase Safety Risks: Canadian Health Policy Institute (CHPI)

TORONTO, ON--(Marketwired - August 22, 2014) - New research published by the Canadian Health Policy Institute (CHPI) finds that though regulatory approvals for new drugs in Europe are faster versus Canada, the rate of discontinuations of new drugs for safety reasons is the same in both jurisdictions. The findings mean that the added drug approval delay in Canada achieves no extra assurance of safety, but instead imposes an unnecessary cost on Canadian patients who are forced to forego the potential health benefits that could be gained from earlier access to new drugs.

The study authored by Dr. Nigel Rawson (Ph.D.) compared drug approval delays in Canada versus Europe, and the rates of discontinuations of new drug products from the market for a safety reason over a 10-year period (2003-2012) using data from Health Canada and the European Medicines Agency.

Rawson found that over the 10-year period from 2003 to 2012, 186 new drugs were approved by Health Canada compared with 189 by the European Medicines Agency. The median approval delay for the new drugs approved in Canada was 391 days compared with 338 days for new drugs approved in Europe. However, the rate of discontinuation of these new drugs for safety reasons was 1.6% in both jurisdictions.

A comparison of jurisdictional experience between consecutive five-year periods showed that the Canadian median review time exceeded the European median by more than 100 days in drugs approved between 2003 and 2007 (503 days versus 349 days), but between 2008 and 2012, the Canadian median delay was only 15 days longer than the European median (353 days versus 338 days).

Despite longer approval times in Canada during the period, the rate of discontinuation in drugs approved in the 2003-07 period among products with a minimum of 18 months of post-approval time was virtually the same in Canada (2.2%) and Europe (2.1%). Just as importantly, despite the speeding up of review times in Canada in 2008-12, none of the drugs approved during this period in either jurisdiction had been discontinued for a safety reason as of the end of June 2014, at which time they had a minimum of 18 months post-approval time.

The study concludes that contrary to the suggestion that decreasing drug review times increases the risk of safety issues, the evidence shows that faster drug approval times in Canada were associated with a reduction in the rate of drugs discontinued for safety reasons versus the previous period (falling from 2.2% in 2003-07 to 0% in 2008-12). In addition, despite Europe having faster drug approval times than Canada throughout the decade, the rate of discontinuation for safety reasons was no higher in Europe than in Canada in any period.

This means that the added drug approval delay in Canada achieved no extra assurance of safety but imposed a cost on Canadian patients who were forced to forego the potential health benefits that could have been gained from earlier access to new drugs.

Open Access Permission

CHPI grants open access permission to republish this news release in whole or in part for use in news articles including a reference to Canadian Health Policy Institute (CHPI) as the publisher. Please include all hyper-linked text where possible.

Get the Study

The study, Do faster drug approvals increase safety risks? Evidence from Canada and Europe 2003-2012, was published at CHPI's free access online journal, Canadian Health Policy and can be downloaded at: www.canadianhealthpolicy.com or www.chpi.ca

Get the Open Access Commentary

A supporting commentary is appended (below) to this news release. CHPI grants open access permission to republish this commentary on the condition that it is published in its entirety without editing and with full attribution to the author. Please include all hyper-linked text where possible.

About CHPI

Canadian Health Policy Institute (CHPI) is a non-profit think-tank funded by independent research grants and unrestricted operating grants from public sector, private sector and non-profit sector sources. CHPI is dedicated to conducting, publishing and communicating evidence-based socio-economic research on health system performance and health policy issues that are important to Canadians.

COMMENTARY

(635 words including title and author credit)

Faster approval of new drugs does not compromise safety

Before any new drug can be sold in Canada, it must be approved as safe and effective by Health Canada. Research shows that the wait for new drug approval in Canada has tended to be longer than in other jurisdictions. However, Health Canada's performance has been improving in recent years and the regulatory delays affecting access to new drugs have shortened substantially in Canada. Some experts have been critical of Health Canada's efforts to achieve more timely regulatory approval of new drugs and have argued that shorter review times will result in lower quality assurance for drug safety.

I examined this concern in a recent study that was published by the Canadian Health Policy Institute (CHPI). The study compared drug approval delays in Canada versus Europe, and the rates of discontinuations of new drug products from the market for a safety reason over a 10-year period (2003-2012) using data from Health Canada and the European Medicines Agency.

The data show that though regulatory approvals for new drugs in Europe are faster versus Canada, the rate of discontinuations of new drugs for safety reasons is the same in both jurisdictions. The findings mean that the added drug approval delay in Canada achieves no extra assurance of safety, but instead imposes an unnecessary cost on Canadian patients who are forced to forego the potential health benefits that could be gained from earlier access to new drugs.

Over the 10-year period from 2003 to 2012, 186 new drugs were approved by Health Canada compared with 189 by the European Medicines Agency. The median approval delay for the new drugs approved in Canada was 391 days compared with 338 days for new drugs approved in Europe. However, the rate of discontinuation of these new drugs for safety reasons was 1.6% in both jurisdictions.

A comparison of jurisdictional experience between consecutive five-year periods showed that the Canadian median review time exceeded the European median by more than 100 days in drugs approved between 2003 and 2007 (503 days versus 349 days), but between 2008 and 2012, the Canadian median delay was only 15 days longer than the European median (353 days versus 338 days).

Despite longer approval times in Canada during the period, the rate of discontinuation in drugs approved in the 2003-07 period among products with a minimum of 18 months of post-approval time was virtually the same in Canada (2.2%) and Europe (2.1%). Just as importantly, despite the speeding up of review times in Canada in 2008-12, none of the drugs approved during this period in either jurisdiction had been discontinued for a safety reason as of the end of June 2014, at which time they had a minimum of 18 months post-approval time.

Contrary to the suggestion that decreasing drug review times increases the risk of safety issues, the evidence shows that as drug approval times in Canada grew shorter there was a reduction in the rate of drugs discontinued for safety reasons versus the previous period (falling from 2.2% in 2003-07 to 0% in 2008-12).

In addition, despite Europe having faster drug approval times than Canada throughout the decade, the rate of discontinuation for safety reasons was no higher in Europe than in Canada in any period.

European and Canadian experience shows that a slower regulatory approval process does not necessarily improve drug safety. Policy-makers need to balance safety concerns against the knowledge that any delay to accessing new drugs also imposes a potential cost on patients in lost health benefits. The evidence shows that by speeding up its approval process, Health Canada has in effect reduced these hidden costs and unintended consequences.

Dr. Nigel SB Rawson, Ph.D. is President of Eastlake Research Group in Oakville, Ontario and an affiliated scholar with Canadian Health Policy Institute (CHPI).

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
The Internet of Things (IoT) promises to evolve the way the world does business; however, understanding how to apply it to your company can be a mystery. Most people struggle with understanding the potential business uses or tend to get caught up in the technology, resulting in solutions that fail to meet even minimum business goals. In his session at @ThingsExpo, Jesse Shiah, CEO / President / Co-Founder of AgilePoint Inc., showed what is needed to leverage the IoT to transform your business. ...
Hadoop as a Service (as offered by handful of niche vendors now) is a cloud computing solution that makes medium and large-scale data processing accessible, easy, fast and inexpensive. In his session at Big Data Expo, Kumar Ramamurthy, Vice President and Chief Technologist, EIM & Big Data, at Virtusa, will discuss how this is achieved by eliminating the operational challenges of running Hadoop, so one can focus on business growth. The fragmented Hadoop distribution world and various PaaS soluti...
The true value of the Internet of Things (IoT) lies not just in the data, but through the services that protect the data, perform the analysis and present findings in a usable way. With many IoT elements rooted in traditional IT components, Big Data and IoT isn’t just a play for enterprise. In fact, the IoT presents SMBs with the prospect of launching entirely new activities and exploring innovative areas. CompTIA research identifies several areas where IoT is expected to have the greatest impac...
Advanced Persistent Threats (APTs) are increasing at an unprecedented rate. The threat landscape of today is drastically different than just a few years ago. Attacks are much more organized and sophisticated. They are harder to detect and even harder to anticipate. In the foreseeable future it's going to get a whole lot harder. Everything you know today will change. Keeping up with this changing landscape is already a daunting task. Your organization needs to use the latest tools, methods and ex...
In his session at DevOps Summit, Tapabrata Pal, Director of Enterprise Architecture at Capital One, will tell a story about how Capital One has embraced Agile and DevOps Security practices across the Enterprise – driven by Enterprise Architecture; bringing in Development, Operations and Information Security organizations together. Capital Ones DevOpsSec practice is based upon three "pillars" – Shift-Left, Automate Everything, Dashboard Everything. Within about three years, from 100% waterfall, C...
Disruptive macro trends in technology are impacting and dramatically changing the "art of the possible" relative to supply chain management practices through the innovative use of IoT, cloud, machine learning and Big Data to enable connected ecosystems of engagement. Enterprise informatics can now move beyond point solutions that merely monitor the past and implement integrated enterprise fabrics that enable end-to-end supply chain visibility to improve customer service delivery and optimize sup...
Wearable devices have come of age. The primary applications of wearables so far have been "the Quantified Self" or the tracking of one's fitness and health status. We propose the evolution of wearables into social and emotional communication devices. Our BE(tm) sensor uses light to visualize the skin conductance response. Our sensors are very inexpensive and can be massively distributed to audiences or groups of any size, in order to gauge reactions to performances, video, or any kind of present...
Even as cloud and managed services grow increasingly central to business strategy and performance, challenges remain. The biggest sticking point for companies seeking to capitalize on the cloud is data security. Keeping data safe is an issue in any computing environment, and it has been a focus since the earliest days of the cloud revolution. Understandably so: a lot can go wrong when you allow valuable information to live outside the firewall. Recent revelations about government snooping, along...
The Workspace-as-a-Service (WaaS) market will grow to $6.4B by 2018. In his session at 16th Cloud Expo, Seth Bostock, CEO of IndependenceIT, will begin by walking the audience through the evolution of Workspace as-a-Service, where it is now vs. where it going. To look beyond the desktop we must understand exactly what WaaS is, who the users are, and where it is going in the future. IT departments, ISVs and service providers must look to workflow and automation capabilities to adapt to growing ...
SYS-CON Events announced today that Dyn, the worldwide leader in Internet Performance, will exhibit at SYS-CON's 16th International Cloud Expo®, which will take place on June 9-11, 2015, at the Javits Center in New York City, NY. Dyn is a cloud-based Internet Performance company. Dyn helps companies monitor, control, and optimize online infrastructure for an exceptional end-user experience. Through a world-class network and unrivaled, objective intelligence into Internet conditions, Dyn ensures...
Business and IT leaders today need better application delivery capabilities to support critical new innovation. But how often do you hear objections to improving application delivery like, “I can harden it against attack, but not on this timeline”; “I can make it better, but it will cost more”; “I can deliver faster, but not with these specs”; or “I can stay strong on cost control, but quality will suffer”? In the new application economy, these tradeoffs are no longer acceptable. Customers will ...
Red Hat has launched the Red Hat Cloud Innovation Practice, a new global team of experts that will assist companies with more quickly on-ramping to the cloud. They will do this by providing solutions and services such as validated designs with reference architectures and agile methodology consulting, training, and support. The Red Hat Cloud Innovation Practice is born out of the integration of technology and engineering expertise gained through the company’s 2014 acquisitions of leading Ceph s...
The free version of KEMP Technologies' LoadMaster™ application load balancer is now available for unlimited use, making it easy for IT developers and open source technology users to benefit from all the features of a full commercial-grade product at no cost. It can be downloaded at FreeLoadBalancer.com. Load balancing, security and traffic optimization are all key enablers for application performance and functionality. Without these, application services will not perform as expected or have the...
As organizations shift toward IT-as-a-service models, the need for managing and protecting data residing across physical, virtual, and now cloud environments grows with it. CommVault can ensure protection &E-Discovery of your data – whether in a private cloud, a Service Provider delivered public cloud, or a hybrid cloud environment – across the heterogeneous enterprise. In his session at 16th Cloud Expo, Randy De Meno, Chief Technologist - Windows Products and Microsoft Partnerships, will disc...
VictorOps is making on-call suck less with the only collaborative alert management platform on the market. With easy on-call scheduling management, a real-time incident timeline that gives you contextual relevance around your alerts and powerful reporting features that make post-mortems more effective, VictorOps helps your IT/DevOps team solve problems faster.